Hormone replacement therapy guideline
Short-term hormone replacement therapy may not be as risky as once thought, according to an updated position statement by the North American Menopause Society. The new analysis, published in NAMS' online journal Menopause, says the risks and benefits of hormone replacement therapy change as women age. Authors say the therapy remains a viable option for the short-term treatment of moderate-to-severe vasomotor symptoms in recently menopausal women. However, women at increased risk for cardiovascular disease or breast cancer should avoid hormone therapy. The updated position statement will likely come as good news to Wyeth, which is still rebounding from a Women's Health Initiative study linking its Prempro product to increased risk of myocardial infarction, stroke and breast cancer (1"The Pink Sheet" Oct. 9, 2006, p. 8)...
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.